机构:[1]School of Chinese Medicine, Hong Kong Baptist University, Hong Kong Special Administrative Region, Kowloon, Hong Kong SAR, China,[2]Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China
This work was supported by the National Natural Science
Foundation of China (82074123, U1903126), the Health and
Medical Research Fund in Hong Kong (16170251), and the Innovation and Technology Fund in Hong Kong (PRP/036/
20FX; MHP/023/20).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类|2 区医学
小类|2 区药学
最新[2025]版:
大类|3 区医学
小类|3 区药学
第一作者:
第一作者机构:[1]School of Chinese Medicine, Hong Kong Baptist University, Hong Kong Special Administrative Region, Kowloon, Hong Kong SAR, China,
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Chen Qilei,Zhou Wenmin,Huang Yueming,et al.Umbelliferone and scopoletin target tyrosine kinases on fibroblast-like synoviocytes to block NF-κB signaling to combat rheumatoid arthritis[J].Frontiers in pharmacology.2022,13:946210.doi:10.3389/fphar.2022.946210.
APA:
Chen Qilei,Zhou Wenmin,Huang Yueming,Tian Yuanyang,Wong Sum Yi...&Chen Hubiao.(2022).Umbelliferone and scopoletin target tyrosine kinases on fibroblast-like synoviocytes to block NF-κB signaling to combat rheumatoid arthritis.Frontiers in pharmacology,13,
MLA:
Chen Qilei,et al."Umbelliferone and scopoletin target tyrosine kinases on fibroblast-like synoviocytes to block NF-κB signaling to combat rheumatoid arthritis".Frontiers in pharmacology 13.(2022):946210